Cord blood study could unlock new HHT treatments
NCT ID NCT05632484
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study collected umbilical cord blood and tissue from 16 newborns who have a parent with hereditary hemorrhagic telangiectasia (HHT), a genetic disorder causing abnormal blood vessels. Researchers aim to grow and compare endothelial cells from these babies with cells from healthy donors to find differences in gene expression. The goal is to identify new targets for future HHT therapies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could identify new drug targets for hereditary hemorrhagic telangiectasia (HHT), potentially leading to better treatments.
- What could go wrong
- This is a very small, early-stage lab study (16 participants) focused on cell collection and gene analysis, not a treatment trial. It may not directly lead to therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
16 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
May 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Newborn whose parents : * are adults * are affiliated to a social security or similar * are not subject to any legal protection measures * Newborn child with one parent who has monitored for HHT confirmed by molecular biology (carrier of a mutation of the SMAD4, ENG or ACVRL1 gene). * Consent signed by the two representatives of parental authority Exclusion Criteria: * One of the two parents opposes donating the umbilical cord blood and the umbilical cord for research * One of the two parents opposes genetic testing * Patient for whom it was not possible to obtain umbilical cord blood after delivery for technical or medical reasons.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hereditary haemorrhagic telangiectasia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Estaing
Clermont-Ferrand, 63100, France
-
Hôpital Femme-mère-Enfant
Bron, 69677, France
-
Hôpital St Eloi
Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.